Amantadine HCl Syrup Rx
Generic Name and Formulations:
Amantadine HCl 50mg/5mL; raspberry flavor.
Various generic manufacturers
Indications for Amantadine HCl Syrup:
Parkinsonism. Drug-induced extrapyramidal reactions.
Parkinsonism monotherapy: initially 100mg twice daily, may increase after 1–2 weeks by 100mg daily. Serious associated illness or high doses of other antiparkinson drugs: 100mg once daily, may increase after 1 to several weeks to 100mg twice daily; max 400mg/day in divided doses. Extrapyramidal disorders: 100mg twice daily; max 300mg/day in divided doses. Renal dysfunction: reduce dose; see literature.
Adjust dose gradually. History of seizures. Heart failure. Orthostatic hypotension. Peripheral edema. Renal (CrCl <50mL/min) or hepatic dysfunction. Psychiatric disorders. Suicidal ideation. History of recurrent eczematoid rash. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with CNS stimulants. Thioridazine may worsen tremor in elderly patients with parkinsonism.
Neuroleptic malignant syndrome (when drug is withdrawn or dose is reduced), nausea, dizziness, insomnia, heart failure, anxiety, irritability, hallucinations, confusion, anorexia, anticholinergic effects, constipation, ataxia, livedo reticularis, peripheral edema, orthostatic hypotension, headache, somnolence, dream abnormality, diarrhea, fatigue.
Formerly known under the brand name Symmetrel.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking